B
10.84
-0.73 (-6.31%)
| Previous Close | 11.57 |
| Open | 11.19 |
| Volume | 443,112 |
| Avg. Volume (3M) | 817,757 |
| Market Cap | 630,984,512 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Bicara Therapeutics Inc. | Bearish | - |
AIStockmoo Score
0.0
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 41.00 (HC Wainwright & Co., 278.23%) | Buy |
| Median | 24.50 (126.02%) | |
| Low | 8.00 (Wells Fargo, -26.20%) | Hold |
| Average | 24.50 (126.02%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 11.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 23 May 2025 | 8.00 (-26.20%) | Hold | 9.27 |
| 17 Apr 2025 | 8.00 (-26.20%) | Sell | 12.16 | |
| HC Wainwright & Co. | 16 May 2025 | 41.00 (278.23%) | Buy | 14.47 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |